Alvocidib (flavopiridol) for the treatment of chronic lymphocytic leukemia

Volume: 25, Issue: 6, Pages: 729 - 734
Published: Apr 7, 2016
Abstract
Alvocidib, which has orphan drug designation in chronic lymphocytic leukemia (CLL) from the FDA and the EMA, is a plant-derived semisynthetic flavone that acts as a cyclin-dependent kinase inhibitor. It induces apoptosis in CLL cells in vitro and was introduced into clinical trials in CLL as an intravenous infusion in 1997, which proved disappointing. Since the drug avidly binds to plasma proteins, higher serum concentrations were required for...
Paper Details
Title
Alvocidib (flavopiridol) for the treatment of chronic lymphocytic leukemia
Published Date
Apr 7, 2016
Volume
25
Issue
6
Pages
729 - 734
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.